US equities |
SPCX $174.74 ▲+2.13% NVDA $241.92 ▲+1.26% MU $1,063.46 ▼-0.05% MRVL $290.14 ▲+6.96% AMD $646.38 ▲+2.32% SNDK $1,674.20 ▼-1.76% TSLA $381.27 ▲+0.67% AVGO $376.67 ▲+3.91%
FinancialContent

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

24.29 -0.86 (-3.42%)
Delayed Quote Updated: 10:21 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals ↗
Via Chartmill
News headline image
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): Strong Growth Meets a High-Quality Technical Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals ↗
Via Chartmill
News headline image
Arcutis (ARQT) Q2 2026 Earnings Call Transcript ↗
ZORYVE franchise revenue surged 59% year-over-year, driving profitability. 
Via The Motley Fool
Topics Earnings Intellectual Property
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup ↗
Via Chartmill
News headline image
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability ↗
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence. 
Via The Motley Fool
Topics Regulatory Compliance
Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
Via Chartmill
News headline image
Arcutis Biotherapeutics Q2 Earnings Call Highlights ↗
Arcutis Biotherapeutics (NASDAQ:ARQT) reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical... 
Via MarketBeat
Topics Earnings
News headline image
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗
Via Chartmill
News headline image
Arcutis Expands Board of Directors with Appointment of Chris Peetz
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗
Via The Motley Fool
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value. 
Via The Motley Fool
News headline image
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗
Via Chartmill
News headline image
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗
Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that... 
Via MarketBeat
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis (ARQT) Q1 2026 Earnings Transcript ↗
Arcutis (ARQT) Q1 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >